Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OTR Therapeutics

Request full access

Accelerating preclinical assets into differentiated clinical therapies

ChinaFounded 2025Biotech & Life Sciences

About OTR Therapeutics

OTR Therapeutics is a biotechnology firm founded in March 2025 by Dr. Zhui Chen, Dr. Shannon Chuai, and Dr. Yuan Shi. The company operates on a model that combines in-house research and development with the strategic acquisition of external innovations. Its operational hub is located in Shanghai. OTR Therapeutics focuses on developing therapies for diseases with significant unmet needs, particularly in oncology, immunology, inflammation, and cardiometabolic conditions.

The company's business model is designed for capital efficiency, aiming to accelerate the development of innovative drugs. This approach involves identifying and acquiring promising preclinical and early-clinical assets to move them into global clinical development. In June 2025, OTR Therapeutics announced it had secured $100 million in a Series A financing round. The funding was backed by investors including True Light Capital, LAV, Pfizer Ventures, and Sirona Capital. These funds are intended to advance the company's pipeline and expand its R&D capabilities. In line with its strategy, the company also acquired a preclinical program with potential for treating neurological diseases.

The founding team brings extensive experience from the biotechnology and pharmaceutical sectors. CEO and Founder, Dr. Zhui Chen, previously co-founded Abbisko Therapeutics and held senior roles at Johnson & Johnson's Shanghai Innovation Center. Co-founder and COO, Dr. Shannon Chuai, has over 20 years of experience in pharmaceuticals and diagnostics, having co-founded Burning Rock Biotech. Dr. Yuan Shi, Co-founder and CSO, has a background in drug discovery and clinical portfolio management from his time at Eli Lilly and co-founding INF Technology.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
56.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Chronic Disease, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2025 $100M $400M Pfizer Ventures · LAV · Sirona Capital · True Light ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

OTR Therapeutics website traffic

Latest recorded traffic for OTR Therapeutics is 930 monthly website visits, up 78.8% over the last three months.

Latest monthly visits930 3-month web change+78.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OTR Therapeutics in its local ecosystem

Live from Dealroom

The OTR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Pfizer Ventures
  • LAV
  • Sirona Capital
  • True Light
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China85.7%
🇺🇸 United States14.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OTR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OTR Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.